An important discovery in brain tumor biology is the identification of isocitrate dehydrogenase (IDH) mutation status as a marker for therapy and prognosis.1 Traditionally, IDH status is determined through immunohistochemistry or gene sequencing on a tissue specimen acquired through brain tissue sampling. Here, IDH3A is linked to brain neoplasm.